ARS Pharmaceuticals (SPRY) Stock Forecast: StockMap's 2-Week Call
SPRY stock forecast: StockMap's model leans Underperform on ARS Pharmaceuticals for the two weeks after the Nov 19 close, toward SPRY trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on SPRY since Aug 21; by chance, a call on the same dates was right 58% of the time.
ARS Pharmaceuticals last closed at $3.36, -8.94% on the session.
Against the IVW growth benchmark the position is -6.61% over the forecast window.
ARS Pharmaceuticals' market cap is $337.79M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -30 (too close to call).
Where SPRY sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
42 daily calls for SPRY so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks ARS Pharmaceuticals in the 2nd percentile on return on equity, where 100 is best.
ARS Pharmaceuticals is classified under Health Care / Biotechnology.
StockMap tracks ARS Pharmaceuticals as the 198th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite ARS Pharmaceuticals ranks 243rd of 394 in the group, against a group median of -0.27.